keyword
MENU ▼
Read by QxMD icon Read
search

"Health technology assessment"

keyword
https://www.readbyqxmd.com/read/28805188/managing-faecal-incontinence-in-people-with-advanced-dementia-resident-in-care-homes-finch-study-a-realist-synthesis-of-the-evidence
#1
Claire Goodman, Christine Norton, Marina Buswell, Bridget Russell, Danielle Harari, Rowan Harwood, Brenda Roe, Jo Rycroft-Malone, Vari M Drennan, Mandy Fader, Michelle Maden, Karen Cummings, Frances Bunn
BACKGROUND: Eighty per cent of care home residents in the UK are living with dementia. The prevalence of faecal incontinence (FI) in care homes is estimated to range from 30% to 50%. There is limited evidence of what is effective in the reduction and management of FI in care homes. OBJECTIVE: To provide a theory-driven explanation of the effectiveness of programmes that aim to improve FI in people with advanced dementia in care homes. DESIGN: A realist synthesis...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28804603/towards-a-more-transparent-hta-process-in-poland-new-polish-hta-methodological-guidelines
#2
Krzysztof Lach, Michal Dziwisz, Cécile Rémuzat, Mondher Toumi
Introduction: Health technology assessment (HTA) in Poland supports reimbursement decisions via the Polish HTA Agency (AOTMiT), whose guidelines were updated in 2016. Methods: We identified key changes introduced by the update and, before guideline publication, analysed discrepancies between AOTMiT assessments and the submitting marketing authorisation holders (MAHs) to elucidate the context of the update. We compared the clarity and detail of the new guidelines versus those of the UK's National Institute for Health and Care Excellence (NICE)...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28804602/balanced-assessment-systems-revisited
#3
Dávid Dankó, Márk Péter Molnár
In 2014, balanced assessment systems (BAS) were proposed as a resource-conscious, 'fit-for-purpose' form of health technology assessment for middle-income countries which lack resources and competences necessary for resource-intensive health technology assessment models. BAS has undergone extensive policy debate in the period since its publication but it has not been critically assessed in a structured form yet. This article aims to describe both the contributions and the weak spots of the original framework and to reflect on them with the intention of further developing the model...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28803589/health-technology-assessment-in-central-eastern-and-south-european-countries-croatia
#4
Mirjana Huic, Romana Tandara Hacek, Ivan Svajger
OBJECTIVES: The aim of this study was to provide a brief, 7-year history of health technology assessment (HTA) implementation in Croatia through national and international activities. METHODS: We used retrospective descriptive analysis of key documents related to the legal framework, process of decision making, and HTA. Analysis of the Agency's plan for and experience with the implementation of a transparent HTA process in Croatia was performed by addressing seven key components of the HTA implementation scorecard framework...
August 14, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28803265/measuring-the-end-of-life-premium-in-cancer-using-individual-ex-ante-willingness-to-pay
#5
S Olofsson, U-G Gerdtham, L Hultkrantz, U Persson
For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some HTA agencies accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short expected remaining lifetime, a so-called end-of-life (EoL) premium. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 individuals in the Swedish general population 20-80 years old using a web-based questionnaire...
August 12, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28795682/effects-of-antenatal-diet-and-physical-activity-on-maternal-and-fetal-outcomes-individual-patient-data-meta-analysis-and-health-economic-evaluation
#6
Ewelina Rogozińska, Nadine Marlin, Louise Jackson, Girish Rayanagoudar, Anneloes E Ruifrok, Julie Dodds, Emma Molyneaux, Mireille Nm van Poppel, Lucilla Poston, Christina A Vinter, Fionnuala McAuliffe, Jodie M Dodd, Julie Owens, Ruben Barakat, Maria Perales, Jose G Cecatti, Fernanda Surita, SeonAe Yeo, Annick Bogaerts, Roland Devlieger, Helena Teede, Cheryce Harrison, Lene Haakstad, Garry X Shen, Alexis Shub, Nermeen El Beltagy, Narges Motahari, Janette Khoury, Serena Tonstad, Riitta Luoto, Tarja I Kinnunen, Kym Guelfi, Fabio Facchinetti, Elisabetta Petrella, Suzanne Phelan, Tânia T Scudeller, Kathrin Rauh, Hans Hauner, Kristina Renault, Christianne Jm de Groot, Linda R Sagedal, Ingvild Vistad, Signe Nilssen Stafne, Siv Mørkved, Kjell Å Salvesen, Dorte M Jensen, Márcia Vitolo, Arne Astrup, Nina Rw Geiker, Sally Kerry, Pelham Barton, Tracy Roberts, Richard D Riley, Arri Coomarasamy, Ben Willem Mol, Khalid S Khan, Shakila Thangaratinam
BACKGROUND: Diet- and physical activity-based interventions in pregnancy have the potential to alter maternal and child outcomes. OBJECTIVES: To assess whether or not the effects of diet and lifestyle interventions vary in subgroups of women, based on maternal body mass index (BMI), age, parity, Caucasian ethnicity and underlying medical condition(s), by undertaking an individual patient data (IPD) meta-analysis. We also evaluated the association of gestational weight gain (GWG) with adverse pregnancy outcomes and assessed the cost-effectiveness of the interventions...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28781881/early-health-technology-assessment-of-magnetic-resonance-guided-high-intensity-focused-ultrasound-ablation-for-the-treatment-of-early-stage-breast-cancer
#7
Floortje M Knuttel, Sèvrin E M Huijsse, Talitha L Feenstra, Chrit T W Moonen, Maurice A A J van den Bosch, Erik Buskens, Marcel J W Greuter, Geertruida H de Bock
BACKGROUND: Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) ablation is in development for minimally invasive treatment of breast cancer. Cost-effectiveness has not been assessed yet. An early health technology assessment was performed to estimate costs of MR-HIFU ablation, compared to breast conserving treatment (BCT). METHODS: An MR-HIFU treatment model using the dedicated MR-HIFU breast system (Sonalleve, Philips Healthcare) was developed...
2017: Journal of Therapeutic Ultrasound
https://www.readbyqxmd.com/read/28780928/comprehensive-assessment-of-complex-technologies-integrating-various-aspects-in-health-technology-assessment
#8
Kristin Bakke Lysdahl, Kati Mozygemba, Jacob Burns, Jan Benedikt Brönneke, James B Chilcott, Sue Ward, Bjørn Hofmann
OBJECTIVES: Despite recent development of health technology assessment (HTA) methods, there are still methodological gaps for the assessment of complex health technologies. The INTEGRATE-HTA guidance for effectiveness, economic, ethical, socio-cultural, and legal aspects, deals with challenges when assessing complex technologies, such as heterogeneous study designs, multiple stakeholder perspectives, and unpredictable outcomes. The objective of this article is to outline this guidance and describe the added value of integrating these assessment aspects...
August 7, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28774374/effectiveness-and-cost-effectiveness-of-serum-b-type-natriuretic-peptide-testing-and-monitoring-in-patients-with-heart-failure-in-primary-and-secondary-care-an-evidence-synthesis-cohort-study-and-cost-effectiveness-model
#9
Maria Pufulete, Rachel Maishman, Lucy Dabner, Syed Mohiuddin, William Hollingworth, Chris A Rogers, Julian Higgins, Mark Dayer, John Macleod, Sarah Purdy, Theresa McDonagh, Angus Nightingale, Rachael Williams, Barnaby C Reeves
BACKGROUND: Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment. OBJECTIVE: To evaluate the clinical effectiveness and cost-effectiveness of BNP-guided therapy compared with symptom-guided therapy in HF patients. DESIGN: Systematic review, cohort study and cost-effectiveness model. SETTING: A literature review and usual care in the NHS...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28772164/multiple-criteria-decision-analysis-mcda-for-evaluating-new-medicines-in-health-technology-assessment-and-beyond-the-advance-value-framework
#10
Aris Angelis, Panos Kanavos
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result in misleading recommendations or decisions. In this paper, a Multiple Criteria Decision Analysis (MCDA) methodological process, based on Multi Attribute Value Theory (MAVT), is adopted for building a multi-criteria evaluation model...
June 20, 2017: Social Science & Medicine
https://www.readbyqxmd.com/read/28770453/examining-the-feasibility-and-utility-of-estimating-partial-expected-value-of-perfect-information-via-a-nonparametric-approach-as-part-of-the-reimbursement-decision-making-process-in-ireland-application-to-drugs-for-cancer
#11
Laura McCullagh, Susanne Schmitz, Michael Barry, Cathal Walsh
BACKGROUND: In Ireland, all new drugs for which reimbursement by the healthcare payer is sought undergo a health technology assessment by the National Centre for Pharmacoeconomics. The National Centre for Pharmacoeconomics estimate expected value of perfect information but not partial expected value of perfect information (owing to computational expense associated with typical methodologies). OBJECTIVE: The objective of this study was to examine the feasibility and utility of estimating partial expected value of perfect information via a computationally efficient, non-parametric regression approach...
August 2, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28761876/sustainability-of-endovenous-iron-deficiency-anaemia-treatment-hospital-based-health-technology-assessment-in-ibd-patients
#12
A Poscia, J Stojanovic, F Kheiraoui, E M Proli, F Scaldaferri, M Volpe, M L Di Pietro, A Gasbarrini, L Fabrizio, S Boccia, C Favaretti
Iron deficiency anaemia (IDA) is the main extraintestinal manifestation affecting patients with inflammatory bowel disease (IBD). The Health Technology Assessment approach was applied to evaluate the sustainability of intravenous (IV) iron formulations in the Italian hospital setting, with particular focus on ferric carboxymaltose. Data on the epidemiology of IBD and associated IDA, in addition to the efficacy and safety of IV iron formulations currently used in Italy, were retrieved from scientific literature...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28757906/lumbosacral-dorsal-rhizotomy-for-spastic-cerebral-palsy-a-health-technology-assessment
#13
(no author information available yet)
BACKGROUND: Cerebral palsy, a spectrum of neuromuscular conditions caused by abnormal brain development or early damage to the brain, is the most common cause of childhood physical disability. Lumbosacral dorsal rhizotomy is a neurosurgical procedure that permanently decreases spasticity and is always followed by physical therapy. The objectives of this health technology assessment were to evaluate the clinical effectiveness, safety, cost effectiveness, and family perspectives of dorsal rhizotomy...
2017: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/28756795/current-environment-for-introducing-health-technology-assessment-in-greece
#14
Chara Kani, Vasilios Kourafalos, Panagiota Litsa
OBJECTIVES: The aim of this study was to describe the current regulatory environment in Greece to evaluate the potential introduction of health technology assessment (HTA) for medicinal products for human use. METHODS: Data sources consist of national legislation on pricing and reimbursement of health technologies to identify the potential need of establishing HTA and its relevant structure. RESULTS: The pricing procedure regarding medicinal products for human use is based on an external reference pricing mechanism which considers the average of the three lowest Euorpean Union prices...
July 31, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28756785/impact-of-health-technology-assessment-in-litigation-concerning-access-to-high-cost-drugs
#15
Alicia Aleman, Ana Perez Galan
OBJECTIVES: The impact of health technology assessment (HTA) in the judicialization of the right of health has not been deeply studied in Latin American countries. The purpose of this study is to review the process of judicialization of the access to high cost drugs in Uruguay and assess the impact HTAs have had on this process. METHODS: The methodology used for this study included a comprehensive literature search in electronic databases, local journals, internal documents developed in the Ministry of Health, as well as conducting interviews with key informants...
July 31, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28756780/an-integrated-perspective-on-the-assessment-of-technologies-integrate-hta
#16
Philip Wahlster, Louise Brereton, Jacob Burns, Björn Hofmann, Kati Mozygemba, Wija Oortwijn, Lisa Pfadenhauer, Stephanie Polus, Eva Rehfuess, Imke Schilling, Gert Jan van der Wilt, Ansgar Gerhardus
OBJECTIVES: Current health technology assessment (HTA) is not well equipped to assess complex technologies as insufficient attention is being paid to the diversity in patient characteristics and preferences, context, and implementation. Strategies to integrate these and several other aspects, such as ethical considerations, in a comprehensive assessment are missing. The aim of the European research project INTEGRATE-HTA was to develop a model for an integrated HTA of complex technologies...
July 31, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28756684/limitations-of-traditional-health-technology-assessment-methods-and-implications-for-the-evaluation-of-novel-therapies
#17
Jason Doctor, Joanna P MacEwan
No abstract text is available yet for this article.
July 31, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28745583/early-health-technology-assessments-in-pharmacogenomics-a-case-example-in-cardiovascular-drugs
#18
Joost W Geenen, Ekaterina V Baranova, Folkert W Asselbergs, Anthonius de Boer, Rick A Vreman, Colin Na Palmer, Anke H Maitland-van der Zee, Anke M Hövels
AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. MATERIALS & METHODS: A decision tree was used. RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1...
August 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28740617/supply-side-and-demand-side-policies-for-biosimilars-an-overview-in-10-european-member-states
#19
Cécile Rémuzat, Anna Kapuśniak, Aleksandra Caban, Dan Ionescu, Guerric Radière, Cyril Mendoza, Mondher Toumi
This study aimed to provide an overview of biosimilar policies in 10 EU MSs. Methods: Ten EU MS pharmaceutical markets (Belgium, France, Germany, Greece, Hungary, Italy, Poland, Spain, Sweden, and the UK) were selected. A comprehensive literature review was performed to identify supply-side and demand-side policies in place in the selected countries. Results: Supply-side policies for biosimilars commonly include price linkage, price re-evaluation, and tendering; the use of internal or external reference pricing varies between countries; health technology assessment is conducted in six countries...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28738015/observational-study-to-estimate-the-changes-in-the-effectiveness-of-bacillus-calmette-gu%C3%A3-rin-bcg-vaccination-with-time-since-vaccination-for-preventing-tuberculosis-in-the-uk
#20
Punam Mangtani, Patrick Nguipdop-Djomo, Ruth H Keogh, Lucy Trinder, Peter G Smith, Paul Em Fine, Jonathan Sterne, Ibrahim Abubakar, Emilia Vynnycky, John Watson, David Elliman, Marc Lipman, Laura C Rodrigues
BACKGROUND: Until recently, evidence that protection from the bacillus Calmette-Guérin (BCG) vaccination lasted beyond 10 years was limited. In the past few years, studies in Brazil and the USA (in Native Americans) have suggested that protection from BCG vaccination against tuberculosis (TB) in childhood can last for several decades. The UK's universal school-age BCG vaccination programme was stopped in 2005 and the programme of selective vaccination of high-risk (usually ethnic minority) infants was enhanced...
July 2017: Health Technology Assessment: HTA
keyword
keyword
9540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"